US Patent Board Allows Mylan’s Challenge to Restasis Patents to Move Forward

March 2, 2018: By Joan McKenna

Mylan announced Feb. 26 that its inter partes review challenge of six patents protecting Allergan’s Restasis will go forward after the US Patent Trial and Appeal Board (PTAB) denied a motion to terminate the challenge.

The St. Regis Mohawk Tribe, which now holds the patents, filed the motion in 2017 on the grounds that it has sovereign immunity from patent challenges.

Allergan transferred Restasis’ patents to the tribe in September 2017 and licensed them back.

Mylan said the PTAB denied the tribe’s motion Feb. 23, holding that the tribe did not establish that tribal sovereign immunity applied to inter partes review proceedings.

Mylan said the patent board tentatively scheduled an oral hearing April 3 and said it would render a final decision on the patentability of the challenged patents by June 6.

In October 2017, the Eastern District of Texas held Allergan’s Restasis patents invalid in the US courts system. The case is currently on appeal.

Dublin-based Allergan has been preparing for the launch of a generic version of Restasis in 2018 by paring costs.

Competitors are also lining up to challenge Allergan’s Botox brand. On March 1, Mylan, of Canonsburg, Pennsylvania, announced plans to bring a lower-priced biosimilar version of Botox to market through a collaboration with Newark, California-based Revance Therapeutics.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Astellas Acquires Quethera, Glaucoma Gene Therapy Candidate in Potential $109 Million Deal

STAAR Surgical Completes $77.9 Million Public Offering

Rheon’s eyeWatch Adjustable Glaucoma Device Implanted in Three UK Patients

Carl Zeiss Meditec Revenues Total $356 Million in Third Quarter of FY2018, a 12.7 Percent Increase

Kedalion Therapeutics Raises $5 Million in Series A Financing

Second Sight Reports 17 Argus II Implantations in Q2-2018; Firm to Focus on Orion System

Iridex Revenues Grow 3 Percent in Q2-2018

Omeros Revenues Drop Steeply with Omidria’s Temporary Loss of Pass-through Status

Shire’s Xiidra Delivers $100 Million in Q2-2018 Revenues, an Increase of 75 Percent

STAAR Posts Q2-2018 Revenues of $33.9 Million, a 55 Percent Increase

Avedro Names Glaukos CEO Thomas Burns to its Board

Aerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million

Alimera’s Q2-2018 Revenues Increase 5 Percent

Presbyopia Therapies’ PRX Meets Phase IIb Endpoints

Clinical Study of Imprimis’ Dropless Formulation Set to Begin in Canada

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT